Dr. Brian Miller, M.D., Medical Director

A Diplomat of the American Board of Psychiatry and Neurology, Dr. Brian Miller is the Medical Director of TMS Therapeutics in San Diego. He earned a B.S. in Psychology from UC Davis, graduating with honors, and completed psychiatric training at UC San Diego. During his last year of residency he served as Chief Resident on the Neuropsychiatry and Behavioral Medicine unit.

Dr. Miller has an active interest in neuromodulation techniques and has practiced electroconvulsive therapy (ECT) for over ten years. He has been named a“Top Doc” by his peers in San Diego Magazine every year since 2011. He has also been listed as a Southern California “Top Doc” by Castle Connolly Medical Ltd in 2012 and 2013. In 2009 he was honored as “Clinician of the Year” at the San Diego County Mental Health Recognition Dinner.

Dr. Miller holds expertise in diagnosing and treating Schizophrenia and other psychotic disorders, as well as Major Depression, Bipolar Disorder, and Substance abuse. He is very enthusiastic about the contributions TMS has made thus far and is pleased to offer TMS as a treatment option.

Off-Label Applications of TMS Therapy

The term “off-label” refers to the absence of FDA clearance or approval for a device or medication.  Pharmaceutical companies and device manufacturers are not allowed to promote a product for any other purpose then what was studied in the FDA trials. Marketing information will list one or more indications or medical conditions for which the drug or device has been shown to be both safe and effective.

However, once a drug or device has been approved for sale for one purpose, physicians are free to prescribe it for any other purpose that in their professional judgment is both safe and effective, and are not limited to official, FDA-approved indications. This off-label prescribing is most commonly done with older, generic medications that have found new uses but have not had the formal applications and studies required by the FDA to approve the drug for these new indications.

TMS is currently FDA approved for treatment of Major Depression. However, there is growing research and clinical application for additional psychiatric and non-psychiatric disorders. TMS Therapeutics is on the cutting edge of new research in developing protocols to discover new applications in addition to expanding on currently known uses.

CURRICULUM VITAE

CURRENT APPOINTMENTS

Alpine Special Treatment Center
Chief Psychiatrist, 2006-present
113 bed Institute for Mental Disease, Mental Health Rehabilitation Center
Facility of the Year 2011, San Diego County Mental Health Recognition Dinner

Sharp HealthCare Grossmont Hospital
Clinical Director Intensive Treatment Program 2001-present Clinical Director Emergency Psychiatric Services 2005-present
Director Electroconvulsive Therapy Services 2004-present

UCSD Department of Psychiatry
2001-present
Assistant Clinical Professor of Psychiatry, UCSD School of Medicine
Previously Salaried Position, Currently Voluntary Appointment

TMS Therapeutics in San Diego
Founder, Medical Director 2012-present

Residential Care Psychiatrist
Various Board and Care Homes, 2001-present

PAST APPOINTMENTS

Crestwood Behavioral Health San Diego
Medical Director, Consultant Psychiatrist 6/14-12/14

Sharp HealthCare Grossmont Hospital
Chief of Psychiatry 2011-2014
Vice-Chief of Psychiatry 2008-2011
Chief of Psychiatry 2003-2006

Sharp-Mesa Vista Hospital
Chief-of-Staff, Elect 2008-2010
Clinical Director Psychiatric Intensive Care Unit 2004-2009
Secretary/ Treasurer Medical Executive Committee 2006-2008
Chair, Peer Review Committee 2008-2010

UCSD Medical Center
Assistant Physician 2001-2006
Clinical Trials Sub-Investigator 2000-2006

Escondido Community Health Center
Psychiatrist 1999-2002

TRAINING

2000- 2001 Chief Resident in Psychiatry, University of California San Diego Medical Center, Neuropsychiatry and Behavioral Medicine Unit
1999-2000 Resident Team Physician, UCSD Dual Diagnosis Demonstration Project
1998-1999 Resident, Department of Psychiatry, UCSD
1997-1998 Internship in Internal Medicine and Psychiatry, UCSD/ Mercy Hospital, San Diego

EDUCATION

1993-1997 University of California, Davis, School of Medicine. Degree: MD.
1990-1993 University Of California, Davis. Degree: BS Psychology with Honors.
1987-1990 American River College, Sacramento. Major: Psychology.

CERTIFICATION AND LICENSURE

2006-current National Provider Identifier #1295089571
2003-current Diplomate, American Board of Psychiatry and Neurology
Recertified Feb 2013 #52004
2001-current Certified in Suboxone/ Subutex #XM6300090
1999-current Medical License, California #A68180
1999-current DEA certification #BM6300090
1998 USMLE Step 3 (score 231, 91 percentile)
1997 USMLE Step 2 (score 236, 90 percentile)
1995 USMLE Step 1 (score 234, 91 percentile)

AWARDS AND HONORS

2011-2014 San Diego Magazine’s “Top Doc” Edition in Psychiatry
2014 Distinguished Fellow, American Psychiatric Association
2012 Castle Connolly, Southern California Edition “Top Doc” in Psychiatry
2009 Clinician of the Year, Mental Health Recognition Dinner
2006 Clinician of the Year, Sharp-Mesa Vista
2006 Teaching Excellence Award, UCSD
2001 APA Resident Reporter, sponsored by Wyeth-Ayerst
2000 Career Directions in Psychiatry, Resident Recipient, sponsored by Pfizer
1997 Central California Psychiatric Society, Medical Student of the Year
1997 Extern, Consultation and Liaison Service, Stanford University
1995-1997 Clerkship Honors in Psychiatry, Surgery, OB/GYN, Pediatrics
1994 Extern, Maudsley Hospital, London England

ACADEMIC ACTIVITIES

04/2015 Treatment Options in Psychiatry: Focus on Neuromodulatory Techniques. San Diego County Conservator and Public Guardian’s Office, Beth Olin, LCSW

03-2015 Anxiety and Depression in Women. Sharp Women’s Health Symposium, San Diego, CA

04/2014 Long-term Stabilization in Psychiatric Disorders, Use of Long-acting Injectable Antipsychotic Medications: Grand Rounds presentation, Grossmont Hospital

04/2014 Treatment of Acute Agitation: Grand Rounds presentation, Grossmont Hospital

2012-2014 Pharmacologic and Non-Pharmacologic Treatment Options in Psychiatry: SDSU School of Social Work, annual presentations, Candy Elson, LCSW

08/2013 Understanding Behavioral Health Needs: Guest Speaker.
Sharp Chula Vista Medical Center, Caroline Etland, RN, PhD

09/2012 Non-Pharmacologic Treatment Options in Psychiatry: Grand Rounds presentation, Grossmont Hospital

09/2012 Personality Disorders: Grossmont Hospital Acute Care Symposium

10/2011 Schizophrenia: Non-Pharmacologic Treatments.
San Diego County Conservator’s Office, Beth Olin, LCSW

2009-2011 Schizophrenia; Drug Development; Long-acting Injectable Antipsychotics; Rezcare Conference for Community Care Facilities, quarterly presentations, Phil Curtis, MSW

02/2011 Schizophrenia: National University, San Diego, Larkin Hoyt, Psy D

05/2007 Chairperson: Long-Term Outcomes of Schizophrenia, APA Annual Meeting, San Diego, CA

05/2007 Opiate Dependence: Grossmont Hospital ED Symposium

10/2007 Depression in Women: AHA Symposium, La Mesa, CA

03/2005 Case Presentation: Recurrent ECT for Chronic Catatonia, Grossmont Hospital

2004-2006 Depression in Women: Sharp Women’s Health Symposium, annual presentations, San Diego, CA

05/2000 Invited Speaker, National Depression and Manic Depression Association, VAMC, La Jolla, CA

MEDIA APPEARANCES

01/27/15 KUSI News: Live Television Interview regarding Implementation
of Laura’s Law in San Diego, Kristen Cusato

09/29/14 Union Tribune interview “Mental Health Services Strained”,
Health Reporter, Paul Sisson

07/16/13 KPBS Radio Interview regarding psychiatric care in San Diego.
Producer Megan Burke, Bureau Chief Alison St. John

03/2013 NBC-7 News: Television Interview regarding implementation of Laura’s Law
in San Diego, Megan Tevrizian

2005 FOX News: Live Television Interview regarding research trials in
schizophrenia

2004 KUSI News: Television Interview regarding Black Box warning for
antidepressants

COMMITTEES

2012-current Advisory Board, Chesed Home, A Project of Hope Village San Diego
2001-current Psychiatric Supervisory Committee, Grossmont Hospital
2002-current Emergency Medicine Supervisory Committee, Grossmont
2005-current Physician Advisory Committee, Grossmont Hospital
2008-2010 Peer Review Committee, Sharp-Mesa Vista
2006-2008 Pharmacy and Therapeutics Committee, Sharp-Mesa Vista
2006-2008 Safe Medication Practices, Sharp-Mesa Vista
2002-2006 Pharmacy and Therapeutics Committee, Grossmont Hospital
1997-2001 Resident Representative, Graduate Education Committee, UCSD
1995-1997 School of Medicine Class Co-President, UC Davis
1993-1995 Library Representative, School of Medicine Class of 1997
1994 Co-Editor, Orientation Manual for incoming medical students

PROFESSIONAL ORGANIZATIONS

1995-present American Psychiatric Association, Distinguished Fellow
1997-present San Diego Psychiatric Society, member
2005-present International Society for ECT and Neurostimulation, member
(formerly the Association for Convulsive Therapy)
2013-present Clinical TMS Society, Charter member
1993-1997 American Medical Student Association, member
1990-1993 American Indian Science and Engineering Society, member

COMMUNITY SERVICE

2011-present Volunteer, National Foundation for Autism Research
2006 Manager, CMRLL t-ball
2005 Assistant Coach, CMRLL t-ball
1999-2000 Volunteer MD, St Vincent de Paul’s homeless shelter
1999-2000 Volunteer MD, Pacific Beach Free Clinic
1995 Director, AMSA Heartbeat Run
1993-1995 Volunteer, AIDS Education Project
1994 Coordinator, Tri-City youth football league fund raising
1992 Volunteer, UCDMC Adolescent Psychiatry Inpatient Ward
1991 Volunteer, NeuroCare in Davis

PUBLICATIONS AND RESEARCH EXPERIENCE

1. Gevirtz, R.N., Alhassoon, O.M., & Miller, B.P. (in press). Biomedical treatments. In J. C. Norcross, G. R. VandenBos, & D. K. Freedheim (Editors-in-Chief), R. Krishnamurthy (Associate Editor), APA handbook of clinical psychology: Vol. 3. Applications and methods. Washington, DC: American Psychological Association.

2. Sub-Investigator Sharp HealthCare. Janssen Care 4 Today Protocol. Utilizing Mobile Health Technology in the treatment of patients with Schizophrenia and Schizoaffective on long-acting injectable antipsychotics. 2015.

3. Miller BP, Garces-Barrella N, RN. Treatment of Catatonia in the Medical ICU with ECT: Delay in Treatment due to Legal “Protections” in California. Poster Presentation at the International Society for ECT and Neurostimulation (ISEN), New York, May 2014.

4. Miller BP. TMS in a Patient with Bipolar Depression Following ECT. Poster Presentation at the U.S Psychiatric and Mental Health Conference, San Diego, Nov 2012.

5. Miller BP, Hoyt L, Allred K. Evaluating the Effectiveness of a Psychosocial Rehabilitation Program for Persons with Severe and Persistent Mental Illness. Poster Presentation at The Meeting of the Minds, San Diego, 2008.

6. Miller BP, Giordano R. Creating a Suicide Risk Assessment Tool for use in the Emergency Department. Poster Presentation at the American Psychiatric Association, San Diego, May 2007.

7. Miller BP, Hoyt L, Allred K. Evaluating the Effectiveness of a Psychosocial Rehabilitation Program for Persons with Severe and Persistent Mental Illness. Poster Presentation at the Institute of Psychiatry, San Diego, Oct 2007.

8. Miller BP, Adams R. Electroconvulsive Therapy: A 12-Month Sample from a Community Hospital. Poster Presentation at the Institute of Psychiatric Services, San Diego, October 2005.

9. Miller BP, Perry W, Moutier C, Robinson S, Feifel D. Rapid oral loading of extended release divalproex in patients with acute mania.
General Hospital Psychiatry, 2005, May-June, 27(3): 218-221.

10. Miller BP, Perry W, Moutier C, Robinson S, Feifel D. Safety and Tolerability of Rapid-Loading Extended Release Divalproex Sodium. Poster Presentation at the APA, New Orleans, May 2001.

11. Matthews SC, Miller BP. Auditory Hallucinations Associated with Topiramate. J Clin Psychiatry, 2001, August, 62(8):653.

12. Servis M, Miller B. Treatment of Psychosis with Prochlorperazine in the ICU setting. Psychosomatics, 1997, Nov-Dec, 38(6):589-90.

13. Principle Investigator, Sharp HealthCare. Bristol-Meyers-Squib Protocol CN138113…Three Fixed Doses of Aripiprazole in the Treatment of Patients with Acute Schizophrenia. 2003.

14. Sub-Investigator, UCSD site for STAR*D. NIMH-funded Sequenced Treatment Alternatives to Relieve Depression, under direction of Sidney Zisook, MD. 2003-2004.

15. Sub-Investigator, Sharp HealthCare. Multiple Phase III and Phase IV trials involving Schizophrenia, Schizoaffective Disorder, Mania, Agitation, and Dementia. Principal Investigator Michael Plopper, MD. 2001-present.

16. Sub-Investigator UCSD, Astra-Zeneca Protocol 5077IL/0099… Safety and Efficacy of Seroquel as Add-on Therapy with Lithium or Divalproex in the Treatment of Acute Mania. 2001.

17. Sub-Investigator UCSD, Eli-Lilly Protocol B4Z-MC-LYAA…Tomoxetine Hydrochloride in Adults Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder. 2001.

18. Sub-Investigator UCSD, Eli-Lilly Protocol B4Z-MC-LYAB…Tomoxetine Hydrochloride in Outpatients with ADHD, Ages 6 to 18 Years. 2001.

19. Sub-Investigator UCSD, Eli-Lilly Protocol B4Z-MC-LYAR(a). Long-Term, Open-Label Safety Study of Tomoxetine Hydrochloride in Adult Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder. 2000.

20. 1999-2000 Team Physician, UCSD Dual Diagnosis Demonstration Project. Led a multidisciplinary team in the treatment of patients with severe dual diagnosis’ using leading edge practices as part of a research project performed in conjunction with the county of San Diego.

21. Research Assistant, UC Davis Department of Neuroscience. Assisted with investigations on sodium channel activity in mammalian retinal cells 1991-1992.